Process Validation vs. Specification Setting For Biologics Impurities Debated At Strategy Forum
This article was originally published in The Pink Sheet Daily
Executive Summary
The ability to validate consistent removal of biopharmaceutical impurities could reduce the need for product specifications, participants at a recent strategy forum agreed. FDA and industry discussed efforts to develop a more coherent regulatory approach to the complex considerations involving biotech impurities.